# A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines

> **NCT05434585** · PHASE1 · UNKNOWN · sponsor: **Suzhou Abogen Biosciences Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** ABO1009-DP
- **BIOLOGICAL:** ABO-CoV.617.2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05434585
- **Lead sponsor:** Suzhou Abogen Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-08
- **Primary completion:** 2022-10-10
- **Final completion:** 2023-08-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05434585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05434585, "A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05434585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*